Erythropoietin for stroke treatment: dead or alive?

Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnerup, Jens, Wersching, Heike, Schäbitz, Wolf-Rüdiger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219325/
https://www.ncbi.nlm.nih.gov/pubmed/21418552
http://dx.doi.org/10.1186/cc10057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219325/
https://www.ncbi.nlm.nih.gov/pubmed/21418552
http://dx.doi.org/10.1186/cc10057

Ejemplares similares